Unique ID issued by UMIN | UMIN000027758 |
---|---|
Receipt number | R000031808 |
Scientific Title | Preoperative gemcitabine plus nab-paclitaxel, concurrent 3D conformal radiation therapy for resectable and borderline resectable pancreatic cancer: Phase II study |
Date of disclosure of the study information | 2017/06/14 |
Last modified on | 2019/12/16 18:46:36 |
Preoperative gemcitabine plus nab-paclitaxel, concurrent 3D conformal radiation therapy for resectable and borderline resectable pancreatic cancer: Phase II study
GEM/nabPTX CRT for advanced pancreatic cancer
Preoperative gemcitabine plus nab-paclitaxel, concurrent 3D conformal radiation therapy for resectable and borderline resectable pancreatic cancer: Phase II study
GEM/nabPTX CRT for advanced pancreatic cancer
Japan |
pancreatic cancer
Hepato-biliary-pancreatic surgery | Vascular surgery |
Malignancy
NO
The objective of this trial is to evaluate the treatment efficacy and safety of gemcitabine plus nab-paclitaxel and concurrent radiation therapy for resectable and borderline resectable pancreatic cancer as a preoperative treatment.
Safety,Efficacy
Phase II
Overall survival
Disease free survival, Response (either radiological or pathological), R0 resection rate, safety, pattern of recurrence
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Induction chemotherapy with GEM/nPTX followed by GEM/nPTX CRT as a preoperative treatment for 3 months.
20 | years-old | <= |
80 | years-old | > |
Male and Female
(1) Patients with resectable and borderline resecable pancreatic cancer (JPS-T3/4)
(2) PS(ECOG):0 or 1
(3) Adequate bone marrow reserves, liver/renal function:
WBC:>=3,500/mm3, <=12,000/mm3
Neutrophil: >=1,500/mm3
platelet: >=100,000/mm3
Hb: >=9.5g/dL
GOT,GPT,ALP: less than 2.5-fold of the upper limit of normal range
TBil: <=1.5mg/dL
Cr: <=1.2ng/dL
Ccr: >=50ml/min
(4) Life expectancy more than 6 months.
(5) Written informed consent.
(1)evident infection
(2)Lung fibrosis or intestinal pneumonia, and anamnesis or imaging findings.
(3)Severe complication(liver cirrhosis, uncontrolled diabetes etc)
(4)the onset of myocardial infarction within 3 months
(5)active synchronous malignancy
(6) Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy
(7)history of severe drug allergy
(8)neuropathy
(9)patients who are judged inappropriate for the entry of the trial by the investigators
50
1st name | Hidenori |
Middle name | |
Last name | Takahashi |
Osaka International Cancer Institute
Gastroenterological Surgery
541-8567
3-1-69, Ohtemae, Chuo-ku, Osaka City, Japan
0669451181
takahasi-hi@mc.pref.osaka.jp
1st name | Hidenori |
Middle name | |
Last name | Takahashi |
Dept. Surgery, Osaka International Cancer Institute
Gastroenterological Surgery
541-8567
3-1-69, Ohtemae, Chuo-ku, Osaka City, Japan
0669451181
takahasi-hi@mc.pref.osaka.jp
Department of Gastroenterological Surgery, Osaka International Cancer Institute
Osaka International Cancer Institute
Self funding
Osaka International Cancer Institute
3-1-69, Otemae, Chuo-ku, Osaka City
06-6945-1181
rinri01@opho.jp
NO
大阪国際がんセンター(大阪府)
2017 | Year | 06 | Month | 14 | Day |
Unpublished
Enrolling by invitation
2017 | Year | 03 | Month | 31 | Day |
2017 | Year | 03 | Month | 31 | Day |
2017 | Year | 06 | Month | 01 | Day |
2022 | Year | 05 | Month | 31 | Day |
2017 | Year | 06 | Month | 14 | Day |
2019 | Year | 12 | Month | 16 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031808